142 related articles for article (PubMed ID: 38589225)
1. Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
Warnock DG; Wallace EL
J Med Genet; 2024 May; 61(6):534-535. PubMed ID: 38589225
[No Abstract] [Full Text] [Related]
2. Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
Lenders M; Brand E
J Med Genet; 2024 May; 61(6):531-533. PubMed ID: 38538083
[No Abstract] [Full Text] [Related]
3. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
Deegan PB
J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
[TBL] [Abstract][Full Text] [Related]
5. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
6. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
Linthorst GE; Aerts JM
J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
[No Abstract] [Full Text] [Related]
7. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
10. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
Linhart A; Dostálová G; Nicholls K; West ML; Tøndel C; Jovanovic A; Giraldo P; Vujkovac B; Geberhiwot T; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Hughes D
Orphanet J Rare Dis; 2023 Oct; 18(1):332. PubMed ID: 37865771
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
13. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
15. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on agalsidase beta in Fabry disease.
Keating GM; Simpson D
BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
[TBL] [Abstract][Full Text] [Related]
18. Agalsidase alfa: specific treatment for Fabry disease.
Mehta A
Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
[TBL] [Abstract][Full Text] [Related]
19. New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage.
Riccio E; Pisani A
Clin Genet; 2023 Mar; 103(3):371-376. PubMed ID: 36373246
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy of Fabry disease.
Clarke JT; Iwanochko RM
Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
